Artificial Intelligence (AI) has a transformative impact on the pharmaceutical landscape, as evidenced by groundbreaking patents in automated cell positioning and predictive modeling. The industry’s dedication to AI innovation is underscored by a notable uptick in strategic deals, signaling a collective push towards technological advancement. Against the backdrop of a decline in job postings, major industry players are actively spearheading AI talent acquisition initiatives. The impact of AI extends beyond the pharmaceutical sector, influencing various industries. GlobalData’s Artificial Intelligence market report helps keep abreast of the latest trends in Artificial Intelligence, market opportunity forecast and the competitive landscape. Buy the report here.
This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding AI. It provides an overview of recent developments in AI-related deals, talent acquisition, and patent filings within the pharmaceutical industry.
Diverse applications of artificial intelligence in pharmaceutical industry
Pharma companies are leveraging artificial intelligence (AI) technologies to innovate and improve their businesses, as evidenced by the latest patents in the field. These patents cover a range of applications, including automated cell positioning, prime editing efficiency prediction, treatment and prevention of respiratory diseases, predictive modeling and control of cell culture, and disinfection and decontamination.
For example, Thread Robotics Inc. has developed a system and method for automated cell positioning, which involves tracking and manipulating gametes within a target region. This technology has the potential to revolutionize cell-based research and therapies.
Yonsei University has patented a system for predicting prime editing efficiency using deep learning. This technology allows researchers to accurately predict the efficiency of prime editing, a gene-editing technique, by analyzing various features.
The University of Houston System has developed compositions and methods for the prevention of respiratory diseases. These methods involve encapsulating STING agonists in liposomes, which can effectively prevent pathogens and improve treatment outcomes.
Another patent focuses on predictive modeling and control of cell culture. This technology allows for the accurate prediction of future values of cell culture attributes and the control of physical inputs to optimize cell culture processes.
Lastly, Chorus, LLC has patented systems and methods for disinfection and decontamination. These systems utilize antimicrobial sensors, generators, and computational systems to effectively generate and monitor antimicrobial agents, ensuring a clean and safe environment.
Overall, these patents highlight the advancements in AI technologies and their applications in the pharmaceutical industry. The acquirer of these patents will benefit from the ability to automate cell positioning, predict editing efficiency, prevent respiratory diseases, optimize cell culture processes, and ensure effective disinfection and decontamination. These technologies have the potential to enhance research, improve treatment outcomes, and streamline pharmaceutical operations.
The industry experienced a 32% decline in the number of AI-related patent applications in Q3 2023 compared with the previous quarter. On an annual basis, the number of AI-related patent applications in the pharmaceutical industry witnessed a drop of 43% compared with Q3 2022.
Strategic deal trends in artificial intelligence in pharmaceutical industry
Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in AI. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of AI in the pharmaceutical industry.
In Q3 2023, the number of AI-related deals in the pharmaceutical industry grew by 14% compared with Q3 2022. On a quarterly basis, there was 27% increase in the number of deals in Q3 2023 compared with the previous quarter.
Impact on hiring
In terms of new job posting, in Q3 2023, the pharmaceutical industry experienced a 38% drop compared with the previous quarter. On an annual basis, job postings also declined by 20%. Notably, computer and mathematical occupations, with a share of 25%, emerged as the top AI-related job roles within the pharmaceutical industry in Q3 2023, with new job postings drop by 19% quarter-on-quarter. Management occupations came in second with a share of 23% in Q3 2023, with new job postings dropping by 41% over the previous quarter. The other prominent AI roles include life, physical, and social science occupations with a 12% share in Q3 2023, and architecture and engineering occupations with a 4% share of new job postings.
Johnson & Johnson, Bristol-Myers Squibb, Novo Nordisk, AstraZeneca, and Merck are among the top companies leading in AI hiring within the pharmaceutical industry.
Countries driving adoption of artificial intelligence in pharmaceutical industry
The US is the leading country in AI adoption within the pharmaceutical industry, boasting the highest number of AI-related patents, jobs, and deals. Meanwhile, the UK, China, South Korea and Canada also maintain significant positions in AI adoption within the pharmaceutical industry.
In conclusion, the pharmaceutical industry is undergoing significant change with a surge in AI-related patents and strategic deals, emphasizing a commitment to integration. This shift is reshaping the job landscape, with industry leaders driving talent acquisition and influencing the future trajectory of innovation, deals, and job opportunities in the sector.
To further understand GlobalData's analysis on artificial intelligence in the pharmaceutical industry, buy the report here.